By RTT News,
January 14, 2014, 02:27:00 AM EDT
(RTTNews.com) - AstraZeneca Plc (AZN.L, AZN) said Tuesday that it now expects 2017 revenues to be broadly in line with 2013 revenues.
AstraZeneca also said it continues to believe a return to growth should come earlier than analyst consensus currently forecasts, following the acquisition of Bristol-Myers Squibb Co.'s ( BMY ) interests in the companies' diabetes alliance - expected to complete during the first quarter of 2014 - and as the alliance's pipeline of new products is progressively launched.
AstraZeneca stated that its Chief Executive Officer, Pascal Soriot, will today present at the JP Morgan Healthcare Conference in San Francisco, CA at 4:30 pm Pacific time.
At the conference, Pascal Soriot will provide an update on the company's development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.
AstraZeneca noted that it has made good progress in accelerating and replenishing its portfolio in its three core therapeutic areas of oncology; cardiovascular/metabolic disease; and respiratory, inflammation and autoimmune diseases. AstraZeneca's late-stage pipeline now comprises 11 Phase III programmes, almost double the number of programmes a year ago, and 27 Phase II programmes. The company has also initiated trials for its cancer immunotherapy combination portfolio for which first data readouts are anticipated in 2014/2015.
AstraZeneca stated that it will provide a more detailed update on its progress at the company's Full Year Results on Thursday, 6 February 2014.
For comments and feedback: contact firstname.lastname@example.org